DK0061802139

Report on transactions with ALK-Abell A/S B shares and associated securities by managerial staffReport on transactions with ALK-Abell A/S B shares and associated securities by managerial staff

Report on transactions with ALK-Abell A/S B shares and associated securities by managerial staff

Accessibility: Skip TopNav ALK (ALKB:DC / OMX: ALK B / AKBLF): In accordance with article 19 in Regulation (EU) No…

2 months ago
ALKs house dust mite tablet (ACARIZAX) now recommended by NICE for use in the UK health systemALKs house dust mite tablet (ACARIZAX) now recommended by NICE for use in the UK health system

ALKs house dust mite tablet (ACARIZAX) now recommended by NICE for use in the UK health system

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE)…

3 months ago
ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS…

6 months ago
ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ALK licenses rights to neffy, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS…

6 months ago